Ability of GLP-1 to decrease food intake is dependent on nutritional status

Physiology and Behavior

Volumn 135, Issue , 2014, Pages 222-229

  Ronveaux, Charlotte C ^a,b   de Lartigue, Guillaume ^a   Raybould, Helen E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b INRA Institut National de la Recherche Agronomique   (France)

Author keywords

Food intake; Glucagon like peptide 1; Receptor trafficking; Vagal afferent neurons

Indexed keywords

GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; MESSENGER RNA; SODIUM CHLORIDE; GLP1R PROTEIN, RAT; GLUCAGON RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL COMPARTMENTALIZATION; CELL MEMBRANE; CONTROLLED STUDY; CYTOPLASM; FOOD INTAKE; IMMUNOBLOTTING; IMMUNOCYTOCHEMISTRY; IMMUNOREACTIVITY; MALE; NONHUMAN; NUTRITIONAL STATUS; POSTPRANDIAL STATE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RAT; SATIETY; SENSORY NERVE CELL; VAGUS NERVE; ANIMAL; DIET RESTRICTION; DRUG EFFECTS; EATING; METABOLISM; NERVE CELL; NODOSE GANGLION; PHYSIOLOGY; WISTAR RAT;

ANIMALS; EATING; FASTING; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; MALE; NEURONS; NODOSE GANGLION; NUTRITIONAL STATUS; POSTPRANDIAL PERIOD; RATS; RATS, WISTAR; RECEPTORS, GLUCAGON;

EID: 84904255671     PISSN: 00319384     EISSN: 1873507X     Source Type: Journal    
DOI: 10.1016/j.physbeh.2014.06.015     Document Type: Article

References (41)

1. Dockray G.J. Luminal sensing in the gut: an overview. J Physiol Pharmacol 2003, 54(Suppl. 4):9-17.
2. Holst J.J. The physiology of glucagon-like peptide 1. Physiol Rev 2007, 87(4):1409-1439.
3. Hansotia T., Drucker D.J. GIP and GLP-1 as incretin hormones: lessons from single and double incretin receptor knockout mice. Regul Pept 2005, 128(2):125-134.
4. Scrocchi L.A., Brown T.J., MaClusky N., Brubaker P.L., Auerbach A.B., et al. Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. Nat Med 1996, 2:1254-1258.
5. Elliott R.M., Morgan L.M., Tredger J.A., Deacon S., Wright J., et al. Glucagon-like peptide-1 (7-36)amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns. J Endocrinol 1993, 138:159-166.
6. Gutzwiller J.P., Goke B., Drewe J., Hildebrand P., Ketterer S., et al. Glucagon-like peptide-1: a potent regulator of food intake in humans. Gut 1999, 44:81-86.
7. Williams D.L., Baskin D.G., Schwartz M.W. Leptin regulation of the anorexic response to glucagon-like peptide-1 receptor stimulation. Diabetes 2006, 55(12):3387-3393.
8. Ruttimann E.B., Arnold M., Hillebrand J.J., Geary N., Langhans W. Intrameal hepatic portal and intraperitoneal infusions of glucagon-like peptide-1 reduce spontaneous meal size in the rat via different mechanisms. Endocrinology 2009, 150:1174-1181.
9. Baumgartner I., Pacheco-Lopez G., Ruttimann E.B., Arnold M., Asarian L., et al. Hepatic-portal vein infusions of glucagon-like peptide-1 reduce meal size and increase c-Fos expression in the nucleus tractus solitarii, area postrema and central nucleus of the amygdala in rats. J Neuroendocrinol 2010, 22:557-563.
10. Sandoval D., Barrera J.G., Stefater M.A., Sisley S., Woods S.C., et al. The anorectic effect of GLP-1 in rats is nutrient dependent. PLoS One 2012, 7:e51870.
11. Neary N.M., Small C.J., Druce M.R., Park A.J., Ellis S.M., et al. Peptide YY3-36 and glucagon-like peptide-17-36 inhibit food intake additively. Endocrinology 2005, 146:5120-5127.
12. Kieffer T.J., McIntosh C.H., Pederson R.A. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 1995, 136(8):3585-3596.
13. Bucinskaite V., Tolessa T., Pedersen J., Rydqvist B., Zerihun L., et al. Receptor-mediated activation of gastric vagal afferents by glucagon-like peptide-1 in the rat. Neurogastroenterol Motil 2009, 21(9):978-e78.
14. 2+ in rat nodose ganglion neurons. Auton Neurosci 2002, 102(1-2):39-44.
15. Dockray G.J., Burdyga G. Plasticity in vagal afferent neurones during feeding and fasting: mechanisms and significance. Acta Physiol (Oxf) 2011, 201(3):313-321.
16. Freeman S.L., Glatzle J., Robin C.S., Valdellon M., Sternini C., et al. Ligand-induced 5-HT3 receptor internalization in enteric neurons in rat ileum. Gastroenterology 2006, 131(1):97-107.
17. Leutenegger C.M., Mislin C.N., Sigrist B., Ehrengruber M.U., Hofmann-Lehmann R., et al. Quantitative real-time PCR for the measurement of feline cytokine mRNA. Vet Immunol Immunopathol 1999, 71:291-305.
18. Dunphy J.L., Taylor R.G., Fuller P.J. Tissue distribution of rat glucagon receptor and GLP-1 receptor gene expression. Mol Cell Endocrinol 1998, 141(1-2):179-186.
19. Vahl T.P., Tauchi M., Durler T.S., Elfers E.E., Fernandes T.M., et al. Glucagon-like peptide-1 (GLP-1) receptors expressed on nerve terminals in the portal vein mediate the effects of endogenous GLP-1 on glucose tolerance in rats. Endocrinology 2007, 148(10):4965-4973.
20. Izumi H., Kaneko Y. Evidence of asymmetric cell division and centrosome inheritance in human neuroblastoma cells. Proc Natl Acad Sci U S A 2012, 109(44):18048-18053.
21. Naslund E., Hellstrom P.M. Appetite signaling: from gut peptides and enteric nerves to brain. Physiol Behav 2007, 92(1-2):256-262.
22. Barrachina M.D., Martinez V., Wei J.Y., Tache Y. Leptin-induced decrease in food intake is not associated with changes in gastric emptying in lean mice. Am J Physiol 1997, 272(3 Pt 2):R1007-R1011.
23. Barrachina M.D., Martinez V., Wang L., Wei J.Y., Tache Y. Synergistic interaction between leptin and cholecystokinin to reduce short-term food intake in lean mice. Proc Natl Acad Sci U S A 1997, 94(19):10455-10460.
24. Barrachina M.D., Martinez V., Wang L., Wei J.Y., Tache Y. EGR1 is a target for cooperative interactions between cholecystokinin and leptin, and inhibition by ghrelin, in vagal afferent neurons. Endocrinology 2010, 151(8):3589-3599.
25. Williams D.L., Baskin D.G., Schwartz M.W. Evidence that intestinal glucagon-like peptide-1 plays a physiological role in satiety. Endocrinology 2009, 150(4):1680-1687.
26. Poleni P.E., Akieda-Asai S., Koda S., Sakurai M., Bae C.R., et al. Possible involvement of melanocortin-4-receptor and AMP-activated protein kinase in the interaction of glucagon-like peptide-1 and leptin on feeding in rats. Biochem Biophys Res Commun 2012, 420(1):36-41.
27. Barrera J.G., D'Alessio D.A., Drucker D.J., Woods S.C., Seeley R.J. Differences in the central anorectic effects of glucagon-like peptide-1 and exendin-4 in rats. Diabetes 2009, 58(12):2820-2827.
28. Tang-Christensen M., Larsen P.J., Goke R., Fink-Jensen A., Jessop D.S., et al. Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats. Am J Physiol 1996, 271(4 Pt 2):R848-R856.
29. Hayes M.R., Kanoski S.E., Alhadeff A.L., Grill H.J. Comparative effects of the long-acting GLP-1 receptor ligands, liraglutide and exendin-4, on food intake and body weight suppression in rats. Obesity (Silver Spring) 2011, 19(7):1342-1349.
30. Kanoski S.E., Rupprecht L.E., Fortin S.M., De Jonghe B.C., Hayes M.R. The role of nausea in food intake and body weight suppression by peripheral GLP-1 receptor agonists, exendin-4 and liraglutide. Neuropharmacology 2012, 62(5-6):1916-1927.
31. Kastin A.J., Akerstrom V. Entry of exendin-4 into brain is rapid but may be limited at high doses. Int J Obes Relat Metab Disord 2003, 27(3):313-318.
32. Jessen L., Aulinger B.A., Hassel J.L., Roy K.J., Smith E.P., et al. Suppression of food intake by glucagon-like peptide-1 receptor agonists: relative potencies and role of dipeptidyl peptidase-4. Endocrinology 2012, 153(12):5735-5745.
33. Baraboi E.D., St-Pierre D.H., Shooner J., Timofeeva E., Richard D. Brain activation following peripheral administration of the GLP-1 receptor agonist exendin-4. Am J Physiol Regul Integr Comp Physiol 2011, 301(4):R1011-R1024.
34. Panjwani N., Mulvihill E.E., Longuet C., Yusta B., Campbell J.E., et al. GLP-1 receptor activation indirectly reduces hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic male ApoE(-/-) mice. Endocrinology 2013, 154(1):127-139.
35. Abbott C.R., Monteiro M., Small C.J., Sajedi A., Smith K.L., et al. The inhibitory effects of peripheral administration of peptide YY(3-36) and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal-brainstem-hypothalamic pathway. Brain Res 2005, 1044(1):127-131.
36. Gaisano G.G., Park S.J., Daly D.M., Beyak M.J. Glucagon-like peptide-1 inhibits voltage-gated potassium currents in mouse nodose ganglion neurons. Neurogastroenterol Motil 2010, 22(4):470-479. [e111].
37. Plamboeck A., Veedfald S., Deacon C.F., Hartmann B., Wettergren A., et al. The effect of exogenous GLP-1 on food intake is lost in male truncally vagotomized subjects with pyloroplasty. Am J Physiol Gastrointest Liver Physiol 2013, 304(12):G1117-G1127.
38. Nakagawa A., Satake H., Nakabayashi H., Nishizawa M., Furuya K., et al. Receptor gene expression of glucagon-like peptide-1, but not glucose-dependent insulinotropic polypeptide, in rat nodose ganglion cells. Auton Neurosci 2004, 110(1):36-43.
39. Burdyga G., de Lartigue G., Raybould H.E., Vahl Morris R., Dimaline R., et al. Cholecystokinin regulates expression of Y2 receptors in vagal afferent neurons serving the stomach. J Neurosci 2008, 28(45):11583-11592.
40. Ranganath L.R., Beety J.M., Morgan L.M., Wright J.W., Howland R., et al. Attenuated GLP-1 secretion in obesity: cause or consequence?. Gut 1996, 38(6):916-919.
41. Morinigo R., Lacy A.M., Casamitjana R., Delgado S., Gomis R., et al. GLP-1 and changes in glucose tolerance following gastric bypass surgery in morbidly obese subjects. Obes Surg 2006, 16(12):1594-1601.